Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    S4 Capital

    MCap

    GBP128m

    Last close

    GBP0.19

    ▲ 2.90 (18.01%)

    Diamyd Medical

    MCap

    SEK1,552m

    Last close

    SEK11.58

    ▲ 1.50 (14.88%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Bull, Bear & Beyond – Sareum Holdings: executive interview

Bull, Bear & Beyond – Sareum Holdings: executive interview

Sareum Holdings — 1 video in collection

More on this equity

Sareum Holdings (AIM: SAR) is a UK-listed drug-discovery company focused on the development of small molecule kinase inhibitors. Its in-house programmes are dual TYK2/JAK1 inhibitors: SDC-1801 for autoimmune diseases and SDC-1802 for cancer. The third development programme is SRA737, a CHK1 inhibitor targeting the DNA damage response network for the treatment of solid tumours. Sareum holds a 27.5% economic interest in SRA737.

Listen on your preferred podcast player below:

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.

< Previous
Next >

You may also be interested in these:

Healthcare

Bull, Bear & Beyond – Mendus: executive interview

Healthcare

Bull, Bear & Beyond – Basilea Pharmaceutica: executive interview